The Harvard Law School Corporate Governance and Financial Regulation blog is getting a workout in the wake of the Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) / Pershing Square efforts to team up to purchase Allergan, Inc. (NYSE:AGN). Pershing Square partnered with Valeant to acquire Allergan In that episode, the activist hedge fund Pershing Square partnered with Valeant, providing them access to inside knowledge that Valeant was going to engage in a takeover bid for Allergan. Pershing Square invested in Allergan, Inc. (NYSE:AGN) before the news was public, pulling down nearly $2 billion in profits. The move was said to cause considerable consternation…
Harvard Law School Blog Sees Path Forward After Allergan
Mark Melin
Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.
Comments are closed.